Back to Search
Start Over
Effect of Dapagliflozin in DAPA-HF According to Background Glucose-Lowering Therapy.
- Source :
- Diabetes Care; Nov2020, Vol. 43 Issue 11, p2878-2881, 4p
- Publication Year :
- 2020
-
Abstract
- <bold>Objective: </bold>To determine whether the benefits of dapagliflozin in patients with heart failure and reduced ejection fraction (HFrEF) and type 2 diabetes in the Dapagliflozin And Prevention of Adverse-Outcomes in Heart Failure trial (DAPA-HF) varied by background glucose-lowering therapy (GLT).<bold>Research Design and Methods: </bold>We examined the effect of study treatment by the use or not of GLT and by GLT classes and combinations. The primary outcome was a composite of worsening heart failure (hospitalization or urgent visit requiring intravenous therapy) or cardiovascular death.<bold>Results: </bold>In the 2,139 type 2 diabetes patients, the effect of dapagliflozin on the primary outcome was consistent by GLT use or no use (hazard ratio 0.72 [95% CI 0.58-0.88] vs. 0.86 [0.60-1.23]; interaction P = 0.39) and across GLT classes.<bold>Conclusions: </bold>In DAPA-HF, dapagliflozin improved outcomes irrespective of use or no use of GLT or by GLT type used in patients with type 2 diabetes and HFrEF. [ABSTRACT FROM AUTHOR]
- Subjects :
- DAPAGLIFLOZIN
TYPE 2 diabetes
HEART failure patients
INTRAVENOUS therapy
PEOPLE with diabetes
BENZENE
RESEARCH
COMBINATION drug therapy
RESEARCH methodology
BLOOD sugar
GLYCOSIDES
MEDICAL cooperation
EVALUATION research
TREATMENT effectiveness
COMPARATIVE studies
RANDOMIZED controlled trials
HOSPITAL care
BLIND experiment
KAPLAN-Meier estimator
METFORMIN
STROKE volume (Cardiac output)
HEART failure
PROPORTIONAL hazards models
LONGITUDINAL method
DISEASE complications
Subjects
Details
- Language :
- English
- ISSN :
- 01495992
- Volume :
- 43
- Issue :
- 11
- Database :
- Complementary Index
- Journal :
- Diabetes Care
- Publication Type :
- Academic Journal
- Accession number :
- 146526411
- Full Text :
- https://doi.org/10.2337/dc20-1402